Life Sciences

QKine

QKine spun-out from the  University of Cambridge in 2016. The company manufactures high quality growth factors and cytokines for stem cell, organoid and regenerative medicine applications.

QKine uses proprietary protein purification and engineering technology to make recombinant proteins in E.coli. 

 

PolyProx

PolyProx Therapeutics is a spin out of the Department of Pharmacology at the University of Cambridge,  and is based on over a decade of research and intellectual property from Founder, Professor Laura Itzhaki’s laboratory. Professor Itzhaki is joined at PolyProx Therapeutics by serial Cambridge biotech entrepreneurs Kevin Moulder as Chief Operating Officer and Andrew […]

Petmedix

PetMedix is applying 30 years of antibody research to develop new pet therapeutics against a wide range of diseases.

Antibody therapeutics have been transformative in human medicine, treating a wide range of diseases including cancers, autoimmune diseases, and inflammatory conditions. The companion animal therapeutics market represents a $14bn opportunity, and one that is already embracing […]

Istesso

Istesso is a drug development company working in the field of immunometabolism. It’s pre-clinical and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune conditions. Istesso’s lead drug, MBS2320, is in a Phase 2a clinical trial in rheumatoid arthritis and has potential applications in other conditions such as ulcerative colitis and […]

Vitamica

Vitamica is seeking to exploit a novel approach for determining the susceptibility of bacteria to antibiotics. Resistance of bacteria to antibiotics is an increasing problem across the world, resulting in poorer healthcare outcomes, higher costs and a reduction in the number of effective drugs.

 

Ikarovec

In August 2018 Ikarovek was formed to commercialise certain orphan assets from Quethera, a spin-out from the University of Cambridge, which was acquired by Astellas Pharma Inc.

Initially Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.

OxSyBio

OxSyBio is developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical applications.

The technology is based on cutting-edge research conducted by Professor Hagan Bayley’s group in the Chemistry Department at the University of Oxford. A leader in the exploration of membrane protein structure and function, Professor Bayley’s group developed […]

MoA Technology

,

MoA Technology Limited is a plant genetics company spun out from the University of Oxford.

NeoPhore

NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. NeoPhore’s drug target rationale is highly validated by genetic evidence in cancer patients and cellular models.
NeoPhore was created to exploit the first of the pipeline of selective, patient-specific drugs generated by the PhoreMost […]

Creavo Medical Technologies

We are delighted to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Medical Technologies, a University of Leeds Spin-out company, as part of a £13.4 million fundraising.

The round was oversubscribed, exceeded Creavo’s funding target and was strongly supported by existing shareholders including IP Group plc, the University of Leeds, and […]

Predictimmune

, ,

We are delighted to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment in Predictimmune Limited, a spinout company from the University of Cambridge. Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes.

Their first offering, PredictImmune-CD, will be […]

Polypharmakos

Cambridge and Kew join forces to find new antimicrobial substances in plants
The Parkwalk-managed University of Cambridge Enterprise Fund IV and Cambridge Enterprise have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the Royal Botanic Gardens, Kew.
Polypharmakos’s mission is to screen natural-product sources of plant, fungal and insect origin for […]

Exonate

,

Exonate are developing a novel approach to modulating new vessel growth.  By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models of angiogenic disease (eg Cancer and wet AMD) but also protect kidney and nerve cells while simultaneously […]

PsyOmics

, ,

PsyOmics  is a University of Cambridge spin-out working to improve the prevention, diagnosis and treatment of neuropsychiatric disorders.

Mental illness accounts for over 15% of the disease burden in developed countries and in England alone, mental illness costs over £51.6bn per annum.

PsyOmics aims to deliver blood based biomarker diagnostics to:

Rapidly diagnose key mental health disorders
[…]

Oxford Endovascular

, ,

Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of […]

Xerion

Xerion Healthcare seeks to commercialise Dr Helen Townley’s Research Group’s work into the use of nano-particles in cancer for therapy, imaging and drug delivery.

The small size of nano-particles means they can passively accumulate in tumours due to the enhanced permeation and retention (EPR) effect, where certain sizes of molecules accumulate more in tumour cells […]

Quethera

,

In August 2018 Quethera, a spin-out from the University of Cambridge, was acquired by Astellas Pharma Inc. Under the terms of the purchase agreement, Astellas may pay up to £85 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders as described here.

Quethera is a gene therapy company developing a novel treatment for glaucoma, developing methods […]

Orthox

, , ,

Orthox is a medical device company founded to exploit FibroFix, a novel silk-based biomaterial platform, for the repair of injuries to cartilage and bone. FibroFix combines exceptional strength and resilience with a porous architecture and chemical structure similar to Fibronectin, an essential component of human cartilage. Orthox believes these properties will allow FibroFix™ to […]

Sphere Medical

Sphere’s products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

PhoreMost

, , ,

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

PhoreMost believes it is uniquely placed […]